Search clinical trials for: BRAF mutant,

Total 997 results

National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Melanoma | Pancreatic Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Cancer | Esophageal Squamous Cell Cancer | BRAF Mutant Colorectal Cancer | Cervical Squamous Cell Cancer | Lung Squamous Cell Cancer

Canada, Italy, Spain, Germany, Netherlands, United States, France
Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Daiichi Sankyo Co., Ltd.

Terminated

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Daiichi Sankyo, Inc.

Terminated

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Lady Davis Institute
Jewish General Hospital

Unknown

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (CURCUMIN)

Lung Cancer

Canada
Rigshospitalet, Denmark
Karolinska University Hospital; Aarhus University Hospital; Sahlgrenska University... and other collaborators

Not yet recruiting

RE-irradiation of Diffuse MIdline Glioma paTients (REMIT)

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Glioma | Pontine Tumors | Brain Tumor, Pediatric | Thalamic Tumor
Sun Yat-sen University

Recruiting

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Malignant Ascites

China
Fudan University

Not yet recruiting

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
EQRx International, Inc.

Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NSCLC

United States
Beijing Pearl Biotechnology Limited Liability Company

Active, not recruiting

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Glioblastoma

China
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
NYU Langone Health
Celldex Therapeutics

Terminated

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Melanoma

United States
Nationwide Children's Hospital
Novartis

Not yet recruiting

Study of Ribociclib and Everolimus in HGG and DIPG

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Nationwide Children's Hospital

Not yet recruiting

Targeted Pediatric High-Grade Glioma Therapy

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
University of Vermont

Completed

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

Polio

United States
InxMed (Shanghai) Co., Ltd.
InventisBio Co., Ltd

Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Solid Tumor

China
Tongji University

Recruiting

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma (ATHEM)

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital

Recruiting

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

Glioma

United States
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
PMV Pharmaceuticals, Inc

Active, not recruiting

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

Healthy Volunteers

United States
St. Jude Children's Research Hospital

Recruiting

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Glioblastoma | Central Nervous System Neoplasms | High Grade Glioma | Ependymoma | Medulloblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | Atypical Teratoid/Rhabdoid Tumor

United States
National Cancer Institute (NCI)

Recruiting

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Glioblastoma, Not Otherwise Specified

United States, Australia, New Zealand, Canada
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (SUPRAMAX)

Glioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Belgium, Switzerland, Netherlands
ES Therapeutics Australia Pty Ltd

Withdrawn

ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors

Epilepsy; Seizure
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Lung Cancer | Lung Cancer Metastatic | Lung Adenocarcinoma | Lung Cancer Stage IV | Recurrent Lung Adenocarcinoma | Recurrent Lung Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Glioma | Oligoastrocytoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | 1p/19q Co-deletion

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Pharmacyclics LLC.

Completed

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
Washington University School of Medicine

Terminated

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer

United States
NantCell, Inc.

Completed

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Italy, France, Russian Federation, Spain, Hungary, Poland, Singapore, Hong Kong, India
National Taiwan University Hospital

Unknown

e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
University Hospital, Essen

Completed

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem)

Malignant Melanoma

Germany, France, Greece, Serbia
Celgene Corporation

Terminated

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Colorectal Cancer

Australia, Belgium, Germany, Italy, Spain, Sweden
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Advanced Cancers

United States
GlaxoSmithKline

Completed

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Cancer

Australia, United States, United Kingdom
Neonc Technologies, Inc.

Not yet recruiting

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

High Grade Glioma | Pineocytoma | Diffuse Midline Glioma, H3 K27M-Mutant | Spinal Cord Tumor | Pediatric Tumor of CNS | Pediatric Tumor of Brain | Pediatric Tumor of Brain Stem | Choroid Plexus Carcinoma, Childhood
National Cancer Institute (NCI)

Recruiting

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Solid Tumors for Phase Ib | Pancreatic Cancer for Phase II | Colorectal Cancer for Phase II

United States, Canada, Australia, Belgium, Germany, Netherlands, Spain
St. Jude Children's Research Hospital
Novartis Pharmaceuticals

Completed

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditions

United States
Yonsei University

Not yet recruiting

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC (ACROSS1)

Non Small Cell Lung Cancer

China
Charite University, Berlin, Germany
Hannover Medical School; Heidelberg University; University of Giessen

Recruiting

Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators (Modulate-CF)

Cystic Fibrosis

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...

Recruiting

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Colorectal Cancer | Pancreatic Cancer

United States
Rain Oncology Inc

Terminated

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (TH-4000)

NSCLC | Non-small Cell Lung Cancer | Non-squamous NSCLC

United States, Australia
First People's Hospital of Hangzhou

Not yet recruiting

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Brain Metastases | EGFR Positive Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Active, not recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

Non-Small Cell Lung Cancer

China, Croatia, Taiwan, Greece, Canada, Thailand, Lebanon, Australia, Hong Kong, Romania, Slovenia, Spain, Jordan, Korea, Republic of, Serbia, Italy, Hungary, India, Turkey, Portugal, Argentina, Malaysia, Colombia, Denmark, Bulgaria, Iceland and more
M.D. Anderson Cancer Center

Completed

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma and other conditions

United States
Clovis Oncology, Inc.
Genentech, Inc.

Terminated

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Non-small Cell Lung Cancer

United States

Search clinical trials for: BRAF mutant,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations